CY1124609T1 - Υγρη συνθεση ανθρωπινου ινωδογονου - Google Patents

Υγρη συνθεση ανθρωπινου ινωδογονου

Info

Publication number
CY1124609T1
CY1124609T1 CY20211100606T CY211100606T CY1124609T1 CY 1124609 T1 CY1124609 T1 CY 1124609T1 CY 20211100606 T CY20211100606 T CY 20211100606T CY 211100606 T CY211100606 T CY 211100606T CY 1124609 T1 CY1124609 T1 CY 1124609T1
Authority
CY
Cyprus
Prior art keywords
liquid composition
fibrogen
human
human fibrogen
composition
Prior art date
Application number
CY20211100606T
Other languages
English (en)
Inventor
Clémence DEBRAIZE
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of CY1124609T1 publication Critical patent/CY1124609T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση προτείνει μια φαρμακευτική σύνθεση η οποία εμπεριέχει μεταξύ 10 και 30g/L ινωδογόνο, μεταξύ 10 και 300 mM αργινίνη και μεταξύ 10 και 300 mM γλουταμάτη. Το pΗ της σύνθεσης εμπεριέχεται επιπλέον μεταξύ 6 και 8.
CY20211100606T 2016-12-22 2021-07-06 Υγρη συνθεση ανθρωπινου ινωδογονου CY1124609T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1663181A FR3061020B1 (fr) 2016-12-22 2016-12-22 Composition de fibrinogene humain
PCT/FR2017/053839 WO2018115800A1 (fr) 2016-12-22 2017-12-22 Composition liquide de fibrinogene humain

Publications (1)

Publication Number Publication Date
CY1124609T1 true CY1124609T1 (el) 2022-07-22

Family

ID=58358663

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100606T CY1124609T1 (el) 2016-12-22 2021-07-06 Υγρη συνθεση ανθρωπινου ινωδογονου

Country Status (16)

Country Link
US (1) US20200093896A1 (el)
EP (1) EP3558381B1 (el)
CN (2) CN117180406A (el)
CY (1) CY1124609T1 (el)
DK (1) DK3558381T3 (el)
ES (1) ES2877848T3 (el)
FR (1) FR3061020B1 (el)
HR (1) HRP20210984T1 (el)
HU (1) HUE055246T2 (el)
LT (1) LT3558381T (el)
MX (2) MX2019007608A (el)
PL (1) PL3558381T3 (el)
PT (1) PT3558381T (el)
RS (1) RS62103B1 (el)
SI (1) SI3558381T1 (el)
WO (1) WO2018115800A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210171587A1 (en) * 2019-12-06 2021-06-10 University Of Wyoming Fibrin particles and methods of forming fibrin particles
EP4384143A1 (en) 2021-08-13 2024-06-19 Biotest AG Fibrinogen compositions and methods of preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE336207C (de) 1916-03-05 1921-04-28 Siemens & Halske Akt Ges Vermittlungsvorrichtung fuer Fernsprechleitungen
ATE321775T1 (de) 1998-09-24 2006-04-15 Pharming Intellectual Pty Bv Reinigung von fibrinogen aus milch durch den einsatz von kationenaustauschchromatographie
WO2000017239A1 (en) 1998-09-24 2000-03-30 Ppl Therapeutics (Scotland) Limited Purification of fibrinogen from fluids by precipitation and hydrophobic chromatography
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
AU2008230476B2 (en) * 2007-03-22 2012-11-01 Km Biologics Co., Ltd. Solid fibrinogen preparation
EP3225252A1 (en) * 2008-05-02 2017-10-04 Laboratoire Français du Fractionnement et des Biotechnologies Treatment of bleeding with low half-life fibrinogen
CN101371921B (zh) * 2008-10-08 2013-02-13 余美伦 一种速溶冻干纤维蛋白原和凝血酶制剂组合物、制备方法及其用途
CN102286095B (zh) * 2011-07-06 2013-08-21 大田华灿生物科技有限公司 纤维蛋白原的制备方法
KR101127127B1 (ko) * 2011-10-27 2012-03-21 주식회사 녹십자 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines

Also Published As

Publication number Publication date
WO2018115800A1 (fr) 2018-06-28
DK3558381T3 (da) 2021-06-28
PT3558381T (pt) 2021-07-01
FR3061020B1 (fr) 2019-05-17
CN117180406A (zh) 2023-12-08
US20200093896A1 (en) 2020-03-26
SI3558381T1 (sl) 2021-11-30
CN110087689B (zh) 2023-09-29
MX2019007608A (es) 2019-08-29
FR3061020A1 (fr) 2018-06-29
EP3558381A1 (fr) 2019-10-30
HUE055246T2 (hu) 2021-11-29
MX2021001361A (es) 2021-04-13
LT3558381T (lt) 2021-08-10
CN110087689A (zh) 2019-08-02
HRP20210984T1 (hr) 2021-09-17
ES2877848T3 (es) 2021-11-17
EP3558381B1 (fr) 2021-04-07
RS62103B1 (sr) 2021-08-31
PL3558381T3 (pl) 2021-10-25

Similar Documents

Publication Publication Date Title
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201992209A1 (ru) Модифицированные циклические динуклеотидные соединения
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1124609T1 (el) Υγρη συνθεση ανθρωπινου ινωδογονου
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
CY1121171T1 (el) Πυρογλουταμικη βορτιοξετινη
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
EA201791467A1 (ru) Водный офтальмологический раствор
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
CY1126054T1 (el) Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων
MY195945A (en) Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition
EA202191180A1 (ru) Производные конденсированного гетероциклического бензодиазепина и их применение